Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
Name
40425_2019_Article_798.pdf
Size
2.41 MB
Format
Adobe PDF
Checksum (MD5)
726aab5284fb02e5859002daf1ef435e
Author(s)
Spranger-Zimmermann, Stefani
Date Issued
November 29, 2019
Journal
Journal for ImmunoTherapy of Cancer
Publisher
BioMed Central
Citation
Ascierto, Paolo A., et al. "Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)." Journal for ImmunoTherapy of Cancer 7, 1 (November 2019): 332 ©2019 Author(s)
Version
Final published version
Abstract
Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune contexture of the tumor microenvironment (TME), drivers of the immune response and mechanisms of tumor resistance to immunity. The development of novel immunotherapeutics and their use in combination with checkpoint inhibitors and other standard of care and novel treatment modalities is an area of particular attention across several tumor types, including melanoma, lung, ovarian, breast, pancreatic, renal, head and neck, brain and non-melanoma skin cancers. The 4th Immunotherapy Bridge meeting (28–29 November, 2018, Naples, Italy) focused on a wide range of evolving topics and trends in the field of cancer immunotherapy and key presentations from this meeting are summarised in this report.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1186/s40425-019-0798-3
